Study of a new drug combination for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new study drug (HS-10504) given along with other treatments for advanced non-small cell lung cancer that has not responded to earlier therapy. The goal is to see if adding this drug can help control the cancer and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) with an EGFR or MET gene change, and your cancer has grown despite previous treatment.
- You have at least one tumor that can be measured on a scan.
- You are generally in good health (able to care for yourself and do light activity), and you are expected to live at least 12 more weeks.
- Your major organs (heart, liver, kidneys, etc.) are working well enough, and you do not have serious untreated medical problems.
- You have not had cancer spread to the brain, other cancers, or a history of certain heart, bleeding, or mental health conditions.
- You are willing to avoid pregnancy (or fathering a child) and to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug (HS-10504) to see how it affects another medicine called midazolam (used for sedation). The goal is to understand how HS-10504 is processed in the body, which may help in future dosing. Participation may provide access to a new treatment option.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.